Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

November 29, 2025 updated by: Zhijun Bao, Fudan University

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention: A Retrospective Observational Study

A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, liraglutide, and dulaglutide, are widely used for the management of type 2 diabetes and obesity. These agents improve glycemic control in part by delaying gastric emptying, but this pharmacologic effect may increase the risk of retained gastric contents (RGC) and aspiration during anesthesia or sedation. In 2023, the American Society of Anesthesiologists (ASA) and the American Society for Gastrointestinal Endoscopy (ASGE) issued recommendations to withhold GLP-1RAs before procedures; however, the optimal discontinuation interval remains uncertain.

Using the electronic medical record system of Huadong Hospital, this retrospective study analyzed patients who underwent upper endoscopy between August 2023 and May 2025 to examine the association between different GLP-1RA exposure patterns and the risk of RGC, providing evidence to inform optimization of pre-procedural discontinuation strategies.

Study Type

Observational

Enrollment (Estimated)

16509

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Danian Ji, M.D.
  • Phone Number: +86-18019094606
  • Email: arctg4@163.com

Study Contact Backup

Study Locations

  • China
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Huadong Hospital, Fudan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients who underwent elective EGD at Huadong Hospital and had complete retrievable information on medication use, medical records, and endoscopy reports

Description

Inclusion Criteria:

  • Undergoing elective upper endoscopy
  • Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom

Exclusion Criteria:

  • Presence of upper gastrointestinal malignancy or obstruction
  • History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.)
  • Emergency endoscopy or non-elective procedures
  • Missing key clinical information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
No GLP-1RA group
Patients with no prescription record of GLP-1RAs, or whose most recent prescription was more than 3 months before the EGD
Other: No Intervention: Observational Cohort
No Intervention: Observational Cohort
GLP-1RA Continued group

Patients who met both of the following criteria:

  1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD;
  2. Underwent painless EGD before August 2024, when our institution had not yet implemented restrictions on GLP-1RA use for painless endoscopy.
Other: No Intervention: Observational Cohort
No Intervention: Observational Cohort
GLP-1RA Held 2 Weeks group

Patients who met both of the following criteria:

  1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD;
  2. Underwent painless EGD after August 2024, when institutional policy mandated that patients discontinue GLP-1RAs for at least 14 days prior to painless EGD.
Other: No Intervention: Observational Cohort
No Intervention: Observational Cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of gastric retention
Time Frame: Immediately at study initiation
Immediately at study initiation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fudan University

Investigators

  • Study Director: Danian Ji, M.D., Huadong Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 10, 2025

Primary Completion (Estimated)

December 15, 2025

Study Completion (Estimated)

December 15, 2025

Study Registration Dates

First Submitted

November 29, 2025

First Submitted That Met QC Criteria

November 29, 2025

First Posted (Actual)

December 11, 2025

Study Record Updates

Last Update Posted (Actual)

December 11, 2025

Last Update Submitted That Met QC Criteria

November 29, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2025K368

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected IPD

IPD Sharing Time Frame

1 year after completion of this study

IPD Sharing Access Criteria

All researchers can require the original data from principal investigator of this study (Email address: arctg4@163.com)

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Retention

Clinical Trials on No Intervention: Observational Cohort

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe